A test of safusidenib for IDH1-mutant glioma that grew during vorasidenib treatment
Official title: Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This trial is testing a drug called safusidenib in people whose glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary grew while they were taking vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary.
Read our full plain-language summary
What the trial team says
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \[BICR\] per modified Response Assessment in Neuro-Oncology \[RANO\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.
Key facts
- Registry number
- NCT07703436
- Stage of testing
- Phase 2
- Conditions studied
- Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma, Oligodendroglioma, Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted, Astrocytoma IDH Mutant Grade 3, Astrocytoma IDH Mutant Grade 2
Where it is running
This trial lists 12 sites.
-
California
- University of California, Los Angeles (Los Angeles)
- University of California, San Francisco (San Francisco)
-
Connecticut
- Yale University (New Haven)
-
Florida
- University of Miami Health (Miami)
-
Indiana
- Indiana University (Indianapolis)
-
Louisiana
- LSU LCMC Health Cancer Center (New Orleans)
-
Massachusetts
- Massachusetts General Hospital (Boston)
-
New Jersey
- Rutgers Cancer Institute (New Brunswick)
-
New York
- NYU Langone Health (New York)
- Columbia University Medical Center (New York)
-
Ohio
- Cleveland Clinic (Cleveland)
- The Ohio State University Comprehensive Cancer Center (Columbus)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.